胃癌（GC）是全球最常见的恶性肿瘤之一，大多数患者在晚期诊断。治疗选择多样化，其中免疫疗法在其中扮演着越来越重要的角色。黑色素瘤抗原相关基因A（MAGE-A）家族是一种癌胚抗原。除了睾丸的生殖细胞和胎盘的滋养层细胞之外，MAGE-A家族在癌组织中高表达，并参与各种生物过程，如癌细胞增殖、分化和转移。此外，癌胚抗原具有良好的免疫原性，可引起体液和细胞免疫应答，在免疫治疗中是一个良好的靶点，具有良好的在胃癌的诊断、治疗和预后上的应用价值。基于MAGE-A的多种靶向治疗药物正在进行Ⅰ或Ⅱ期临床试验，具有良好的安全性和潜在的临床应用价值。随着对MAGE-A靶点在GC临床转化和免疫治疗方面基础研究和临床试验的不断进展，未来将为MAGE-A在胃癌的免疫治疗提供理论基础。

Gastric cancer (GC) is one of the most common malignant tumors worldwide, and most of the patients are diagnosed at the advanced stage. Most of the treating options are comprehensive treatment, in which immunotherapy plays more and more important role. Melanoma antigen-associated gene-A (MAGE-A) family is a kind of cancer testis antigens. Except in germ cells of testis and trophoblast cells of placenta, MAGE-A family is highly expressed in cancerous tissues and participates in a variety of biological processes, such as cancer cell proliferation, differentiation and metastasis. In addition, cancer testis antigen also possesses good immunogenicity, which can induce humoral and cellular immune responses, is a good target for immunotherapy, and has good application value in the diagnosis, treatment and prognosis of GC. A variety of targeted therapeutic drugs based on MAGE-A are in phase I or II clinical trials, it has good safety and potential clinical application value. With the continuous progress of clinical trials and basic research on MAGE-A targets in GC, it is expected to provide a theoretical basis for clinical transformation and immunotherapy of MAGE-A in the future.